Ramakumar Mayampurath
Known title: SVP, CFO, TreasurerCIK: 0001859332
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 12, 2026
Roche presents new Phase III data and FDA approval. Roche reported new one-year Phase III data for vamikibart in treating uveitic macular edema, a condition causing vision loss. Additionally, the FDA approved Tecentriq for adjuvant treatment of stage III colon cancer. These developments reflect ongoing progress in the company's clinical pipeline and regulatory approvals.
Transaction History
| MKSI | ▼ Sell | Open Market | 8,810 | $2.8M | 5/22/2026 | View on chart |
| MKSI | ▲ Buy | Option Exercise | 2,958 | — | 2/17/2026 | View on chart |
| MKSI | ▲ Buy | Option Exercise | 2,702 | — | 2/17/2026 | View on chart |
| MKSI | ▼ Sell | Tax Withholding | 2,516 | $656K | 2/17/2026 | View on chart |
| MKSI | ▲ Buy | Option Exercise | 8,295 | — | 11/17/2025 | View on chart |
| MKSI | ▼ Sell | Tax Withholding | 2,628 | $375K | 11/17/2025 | View on chart |
| ROG | ▼ Sell | Tax Withholding | 80 | $9K | 5/1/2024 | View on chart |
| ROG | ▲ Buy | Grant | 4,270 | $0 | 2/19/2024 | View on chart |
| ROG | ▼ Sell | Tax Withholding | 291 | $34K | 2/14/2024 | View on chart |
| ROG | ▼ Sell | Tax Withholding | 42 | $5K | 2/10/2024 | View on chart |
| ROG | ▼ Sell | Tax Withholding | 383 | $46K | 2/9/2024 | View on chart |
| ROG | ▼ Sell | Open Market | 1,200 | $193K | 5/3/2023 | View on chart |
| ROG | ▼ Sell | Tax Withholding | 83 | $13K | 5/1/2023 | View on chart |
| ROG | ▼ Sell | Tax Withholding | 316 | $47K | 2/14/2023 | View on chart |
| ROG | ▼ Sell | Tax Withholding | 47 | $7K | 2/12/2023 | View on chart |
| ROG | ▼ Sell | Tax Withholding | 51 | $8K | 2/10/2023 | View on chart |
| ROG | ▼ Sell | Tax Withholding | 37 | $6K | 2/9/2023 | View on chart |
| ROG | ▲ Buy | Grant | 3,724 | $0 | 2/9/2023 | View on chart |
| ROG | ▲ Buy | Grant | 109 | $0 | 2/9/2023 | View on chart |
| ROG | ▲ Buy | Grant | 9,530 | $0 | 12/8/2022 | View on chart |
| ROG | ▼ Sell | Tax Withholding | 88 | $24K | 5/1/2022 | View on chart |
| ROG | ▲ Buy | Grant | 3,250 | $0 | 2/14/2022 | View on chart |
| ROG | ▼ Sell | Tax Withholding | 42 | $11K | 2/12/2022 | View on chart |
| ROG | ▼ Sell | Tax Withholding | 46 | $13K | 2/10/2022 | View on chart |
| ROG | ▲ Buy | Grant | 1,005 | $0 | 2/9/2022 | View on chart |
| ROG | ▼ Sell | Tax Withholding | 306 | $83K | 2/9/2022 | View on chart |
| ROG | ▼ Sell | Tax Withholding | 65 | $18K | 2/7/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
MKS Inc. Stock Rebounds Amid Semiconductor Sector Recovery
MKS Inc. shares are trading higher as the broader semiconductor sector rebounds from recent weakness. This recovery follows comments from NY Fed President Williams suggesting room for further policy adjustments. While the stock is currently trading near its 52-week low, analysts maintain a wide range of price targets for the company.
MKS Inc. Stock Rebounds Amid Semiconductor Sector Recovery. MKS Inc. shares are trading higher as the broader semiconductor sector rebounds from recent weakness. This recovery follows comments from NY Fed President Williams suggesting room for further policy adjustments. While the stock is currently trading near its 52-week low, analysts maintain a wide range of price targets for the company.